Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2024 16:45 ET | Source: Osteal Therapeutics

Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting

DALLAS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
August 05, 2024 12:28 ET | Source: Osteal Therapeutics

Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting

DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
June 05, 2024 09:00 ET | Source: Osteal Therapeutics

Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate

Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
December 05, 2023 07:00 ET | Source: Osteal Therapeutics

Osteal Therapeutics’ VT-X7 Receives FDA’s Breakthrough Therapy Designation for the treatment of periprosthetic joint infection of the hip and knee and completes enrollment of the pivotal APEX-2 trial

DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for VT-X7, Osteal Therapeutics’ (“Osteal’s”) investigational drug...
September 28, 2023 07:14 ET | Source: Osteal Therapeutics

BioNTX Names Osteal Therapeutics 2023 Rising Star

President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award follows the announcement by Osteal of an oversubscribed $23M...
September 21, 2023 08:23 ET | Source: Osteal Therapeutics

Osteal Therapeutics Closes $23M Series C Financing

Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM Capital, Prism Ventures and Medvest Capital. Proceeds...
February 07, 2023 10:31 ET | Source: Osteal Therapeutics

Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection

DALLAS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal...
December 29, 2022 08:00 ET | Source: Osteal Therapeutics

Osteal Therapeutics Announces Leadership Team Appointments

DALLAS, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination products for musculoskeletal...
November 04, 2022 08:00 ET | Source: Osteal Therapeutics

Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection

DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal...
March 08, 2022 08:50 ET | Source: Osteal Therapeutics

Osteal Therapeutics Closes an Oversubscribed $30 Million Series B Financing to Advance Platform Therapy for Treatment of Musculoskeletal Infection

Series B financing led by HM Capital and joined by returning investors JJDC and Medvest Capital Proceeds will support clinical development of lead candidate, VT-X7 for periprosthetic joint infection....